Cosmo’s results swing sharply as one-off project deals fade and the company shifts focus to repeatable royalty and manufacturing income, sparking a big market sell-off. With new approvals, a US launch for its AI-assisted endoscopy system, and key clinical readouts ahead, the next year could clarify whether this is a temporary dip or a turning point.Read more
Key Takeaways Heavy reliance on a few key drugs and regulatory uncertainties create risks for long-term growth and profitability despite strong demand and innovation efforts. Mounting pricing pressures, competition from generics, and slow regulatory approval could erode margins and limit international expansion opportunities.Read more
Key Takeaways Evolving MedTech platforms and strategic global partnerships are unlocking new markets, driving recurring revenue growth and expanding Cosmo's presence beyond its current therapy areas. Accelerated innovation, AI integration, and a strong clinical pipeline position Cosmo for high-margin, sustained earnings growth and increased resilience to market shifts.Read more
Key Takeaways Strategic expansion in AI-powered diagnostics and proprietary drug delivery platforms positions Cosmo for sustained revenue growth, margin expansion, and competitive differentiation in global healthcare markets. Advances in specialty pharmaceuticals and digital transformation, supported by global partnerships, provide multiple growth drivers, diversified earnings streams, and enhanced operational efficiency.Read more
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
